Skip to main content
. Author manuscript; available in PMC: 2020 Sep 20.
Published in final edited form as: Curr Cancer Drug Targets. 2020;20(4):253–270. doi: 10.2174/1568009619666191202101330

Fig. 11.

Fig. 11.

Hsp90α/β-selective inhibitors – TAS-116 and KUNB31, the first N-terminal, Hsp90α/β and Hsp90β isoform-selective inhibitors, respectively.